Detection of Proteolytic Signatures for Parkinson's Disease

References

• De Rijk MC , LaunerLJ, BergerKet al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the Elderly Research Group. Neurology54(11 Suppl. 5), S21–S23 (2000).
   PubMed Web of Science ®Google Scholar
• Jankovic J . Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry79(4), 368–376 (2008).
   PubMed Web of Science ®Google Scholar
• Bjorklund A , DunnettSB. Dopamine neuron systems in the brain: an update. Trends Neurosci.30(5), 194–202 (2007).
   PubMed Web of Science ®Google Scholar
• Kalia LV , KaliaSK, LangAE. Disease-modifying strategies for Parkinson's disease. Mov. Disord.30(11), 1442–1450 (2015).
   PubMed Web of Science ®Google Scholar
• Hart RG , PearceLA, RavinaBM, YalthoTC, MarlerJR. Neuroprotection trials in Parkinson's disease: systematic review. Mov. Disord.24(5), 647–654 (2009).
   PubMed Web of Science ®Google Scholar
• Iranzo A , ValldeoriolaF, LomenaFet al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol.10(9), 797–805 (2011).
   PubMed Web of Science ®Google Scholar
• Braak H , GhebremedhinE, RubU, BratzkeH, Del TrediciK. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res.318(1), 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• Abbott RD , PetrovitchH, WhiteLRet al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology57(3), 456–462 (2001).
   PubMed Web of Science ®Google Scholar
• Agarwal PA , StoesslAJ. Biomarkers for trials of neuroprotection in Parkinson's disease. Mov. Disord.28(1), 71–85 (2013).
   PubMed Web of Science ®Google Scholar
• Gerlach M , MaetzlerW, BroichKet al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J. Neural. Transm.119(1), 39–52 (2012).
   PubMed Web of Science ®Google Scholar
• Litvan I , GoetzCG, JankovicJet al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol.54(8), 937–944 (1997).
   PubMedGoogle Scholar
• Hughes AJ , DanielSE, Ben-ShlomoY, LeesAJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain125(Pt 4), 861–870 (2002).
   PubMed Web of Science ®Google Scholar
• Mcnaught KS , JacksonT, JnobaptisteR, KapustinA, OlanowCW. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology66(10 Suppl. 4), S37–S49 (2006).
   PubMed Web of Science ®Google Scholar
• Snyder H , WolozinB. Pathological proteins in Parkinson's disease: focus on the proteasome. J. Mol. Neurosci.24(3), 425–442 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang NY , TangZ, LiuCW. Alpha-synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J. Biol. Chem.283(29), 20288–20298 (2008).
   PubMed Web of Science ®Google Scholar
• Schapira AH , TolosaE. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol.6(6), 309–317 (2010).
   PubMed Web of Science ®Google Scholar
• Mahrus S , TrinidadJC, BarkanDT, SaliA, BurlingameAL, WellsJA. Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell134(5), 866–876 (2008).
   PubMed Web of Science ®Google Scholar
• Spillantini MG , CrowtherRA, JakesR, CairnsNJ, LantosPL, GoedertM. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett.251(3), 205–208 (1998).
   PubMed Web of Science ®Google Scholar
• Hoehn MM , YahrMD. Parkinsonism: onset, progression, and mortality. 1967. Neurology57(10 Suppl. 3), S11–S26 (2001).
   PubMed Web of Science ®Google Scholar
• Emre M , AarslandD, BrownRet al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Move. Disord.22(12), 1689–1707 (2007).
   PubMed Web of Science ®Google Scholar
• Barton B , GrabliD, BernardBet al. Clinical validation of movement disorder society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov. Disord.27(2), 248–253 (2012).
   PubMed Web of Science ®Google Scholar
• Del Campo M , MollenhauerB, BertolottoAet al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark. Med.6(4), 419–430 (2012).
   PubMed Web of Science ®Google Scholar
• Gilman S , WenningGK, LowPAet al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology71(9), 670–676 (2008).
   PubMed Web of Science ®Google Scholar
• Heegaard NH , JuliaT, Tanassi SaraBechet al. CSF-alpha-synuclein in the differential diagnosis of parkinsonian syndromes. Fut. Neurol.9(5), 525–532 (2014).
   Google Scholar
• Atwell S , WellsJA. Selection for improved subtiligases by phage display. Proc. Natl Acad. Sci. USA96(17), 9497–9502 (1999).
   PubMed Web of Science ®Google Scholar
• Abrahmsen L , TomJ, BurnierJ, ButcherKA, KossiakoffA, WellsJA. Engineering subtilisin and its substrates for efficient ligation of peptide bonds in aqueous solution. Biochemistry30(17), 4151–4159 (1991).
   PubMed Web of Science ®Google Scholar
• Chang TK , JacksonDY, BurnierJP, WellsJA. Subtiligase: a tool for semisynthesis of proteins. Proc. Natl Acad. Sci. USA91(26), 12544–12548 (1994).
   PubMed Web of Science ®Google Scholar
• Fang L , JiaKZ, TangYL, MaDY, YuM, HuaZC. An improved strategy for high-level production of TEV protease in Escherichia coli and its purification and characterization. Protein Expr. Purif.51(1), 102–109 (2007).
   PubMed Web of Science ®Google Scholar
• Maclean B , TomazelaDM, ShulmanNet al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics26(7), 966–968 (2010).
   PubMed Web of Science ®Google Scholar
• Farrah T , DeutschEW, KreisbergRet al. PASSEL: the PeptideAtlas SRMexperiment library. Proteomics12(8), 1170–1175 (2012).
   PubMed Web of Science ®Google Scholar
• Harrington MG . Disease Markers of the Nervous System.IOS Press, Amsterdam, The Netherlands, 22 (2006).
   Google Scholar
• Laslop A , DoblingerA, WeissU. Proteolytic processing of chromogranins. Adv. Exp. Med. Biol.482, 155–166 (2000).
   PubMed Web of Science ®Google Scholar
• Taylor A . Aminopeptidases: structure and function. FASEB J.7(2), 290–298 (1993).
   PubMed Web of Science ®Google Scholar
• Wiita AP , SeamanJE, WellsJA. Global analysis of cellular proteolysis by selective enzymatic labeling of protein N-termini. Methods Enzymol.544, 327–358 (2014).
   PubMed Web of Science ®Google Scholar
• Gevaert K , GoethalsM, MartensLet al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat. Biotech.21(5), 566–569 (2003).
   PubMed Web of Science ®Google Scholar
• Doucet A , KleifeldO, KizhakkedathuJN, OverallCM. Identification of proteolytic products and natural protein N-termini by Terminal Amine Isotopic Labeling of Substrates (TAILS). Methods Mol. Biol.753273–287 (2011).
   PubMedGoogle Scholar
• Roher AE , LowensonJD, ClarkeSet al. Beta-amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl Acad. Sci. USA90(22), 10836–10840 (1993).
   PubMed Web of Science ®Google Scholar
• Bayer TA , CappaiR, MastersCL, BeyreutherK, MulthaupG. It all sticks together – the APP-related family of proteins and Alzheimer's disease. Mol. Psychiatry4(6), 524–528 (1999).
   PubMed Web of Science ®Google Scholar
• Palsdottir A , AbrahamsonM, ThorsteinssonLet al. Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet2(8611), 603–604 (1988).
   PubMed Web of Science ®Google Scholar
• Benson MD , LiepnieksJ, UemichiT, WheelerG, CorreaR. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat. Genet.3(3), 252–255 (1993).
   PubMed Web of Science ®Google Scholar
• Haltia M , PrelliF, GhisoJet al. Amyloid protein in familial amyloidosis (Finnish type) is homologous to gelsolin, an actin-binding protein. Biochem. Biophys. Res. Commun.167(3), 927–932 (1990).
   PubMed Web of Science ®Google Scholar
• Karring H , PoulsenET, RunagerKet al. Serine protease HtrA1 accumulates in corneal transforming growth factor beta induced protein (TGFBIp) amyloid deposits. Mol. Vis.19861–876 (2013).
   PubMed Web of Science ®Google Scholar
• Mita S , MaedaS, ShimadaK, ArakiS. Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy. J. Biochem.100(5), 1215–1222 (1986).
   PubMed Web of Science ®Google Scholar
• Hatters DM , WilsonMR, Easterbrook-SmithSB, HowlettGJ. Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin. Eur. J. Biochem.269(11), 2789–2794 (2002).
   PubMedGoogle Scholar
• Merlini G , BellottiV. Molecular mechanisms of amyloidosis. N. Engl. J. Med.349(6), 583–596 (2003).
   PubMed Web of Science ®Google Scholar
• Petkova AT , LeapmanRD, GuoZ, YauWM, MattsonMP, TyckoR. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science307(5707), 262–265 (2005).
   PubMed Web of Science ®Google Scholar
• Dzwolak W , SmirnovasV, JansenR, WinterR. Insulin forms amyloid in a strain-dependent manner: an FT-IR spectroscopic study. Protein Sci.13(7), 1927–1932 (2004).
   PubMed Web of Science ®Google Scholar
• Surmacz-Chwedoruk W , NieznanskaH, WojcikS, DzwolakW. Cross-seeding of fibrils from two types of insulin induces new amyloid strains. Biochemistry51(47), 9460–9469 (2012).
   PubMed Web of Science ®Google Scholar
• Macchi F , HoffmannSV, CarlsenMet al. Mechanical stress affects glucagon fibrillation kinetics and fibril structure. Langmuir.27(20), 12539–12549 (2011).
   PubMed Web of Science ®Google Scholar
• Wiita AP , HsuGW, LuCM, EsenstenJH, WellsJA. Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling. Proc. Natl Acad. Sci. USA111(21), 7594–7599 (2014).
   PubMed Web of Science ®Google Scholar
• Shimbo K , HsuGW, NguyenHet al. Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis. Proc. Natl Acad. Sci. USA109(31), 12432–12437 (2012).
   PubMed Web of Science ®Google Scholar
• Bernard G , BreittmayerJP, De MatteisMet al. Apoptosis of immature thymocytes mediated by E2/CD99. J. Immunol.158(6), 2543–2550 (1997).
   PubMed Web of Science ®Google Scholar
• Cerisano V , AaltoY, PerdichizziSet al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell–cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene23(33), 5664–5674 (2004).
   PubMed Web of Science ®Google Scholar
• Ringman JM , SchulmanH, BeckerCet al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch. Neurol.69(1), 96–104 (2012).
   PubMedGoogle Scholar
• Hall S , OhrfeltA, ConstantinescuRet al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol.69(11), 1445–1452 (2012).
   PubMedGoogle Scholar
• Alves G , LangeJ, BlennowKet al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology82(20), 1784–1790 (2014).
   PubMed Web of Science ®Google Scholar
• Bech S , HjermindLE, SalvesenLet al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat. Disord.18(1), 69–72 (2012).
   PubMed Web of Science ®Google Scholar
• Magdalinou N , LeesAJ, ZetterbergH. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J. Neurol. Neurosurg. Psychiatry85(10), 1065–1075 (2014).
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ , Alonso-NavarroH, Garcia-MartinE, AgundezJA. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci.8, 369 (2014).
   PubMed Web of Science ®Google Scholar
• Magdalinou NK , PatersonRW, SchottJMet al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry86(11), 1240–1247 (2015).
   PubMed Web of Science ®Google Scholar
• Eckhard U , MarinoG, ButlerGS, OverallCM. Positional proteomics in the era of the human proteome project on the doorstep of precision medicine. Biochimie. doi:10.1016/j.biochi.2015.10.018 (2015) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar